Natera, Inc. (NASDAQ:NTRA) Receives Average Rating of “Buy” from Analysts

Natera, Inc. (NASDAQ:NTRA) has received a consensus rating of “Buy” from the seventeen analysts that are presently covering the company, MarketBeat reports. Seventeen analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $165.88.

A number of analysts have recently weighed in on the stock. TD Cowen boosted their target price on shares of Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Guggenheim boosted their price objective on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, January 17th. StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Canaccord Genuity Group boosted their target price on Natera from $165.00 to $180.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. Finally, Piper Sandler raised their price target on Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, November 18th.

Natera Trading Up 1.6 %

NTRA stock opened at $173.39 on Monday. The firm has a fifty day moving average price of $167.75 and a 200 day moving average price of $143.43. Natera has a fifty-two week low of $68.03 and a fifty-two week high of $183.00. The firm has a market cap of $22.89 billion, a PE ratio of -98.52 and a beta of 1.66. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Insider Transactions at Natera

In related news, insider John Fesko sold 669 shares of the stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $159.60, for a total value of $106,772.40. Following the transaction, the insider now owns 114,142 shares of the company’s stock, valued at $18,217,063.20. This represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael Burkes Brophy sold 43,502 shares of Natera stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $176.88, for a total value of $7,694,633.76. Following the sale, the chief financial officer now directly owns 70,629 shares of the company’s stock, valued at approximately $12,492,857.52. This trade represents a 38.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 305,454 shares of company stock valued at $51,290,625. 7.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Principal Securities Inc. lifted its position in shares of Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after purchasing an additional 59 shares during the period. Gladstone Institutional Advisory LLC raised its stake in Natera by 1.7% in the fourth quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company’s stock worth $574,000 after buying an additional 61 shares in the last quarter. Silver Oak Securities Incorporated lifted its holdings in Natera by 3.1% during the fourth quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company’s stock worth $470,000 after buying an additional 89 shares during the period. Covestor Ltd boosted its position in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 95 shares in the last quarter. Finally, Blue Trust Inc. increased its holdings in shares of Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 97 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.